October 29, 2018 Odette Audet

TSO3 Named Winner of South Carolina Innovation Award

Myrtle Beach, SC and Quebec City, Canada – October 29, 2018 – TSO3 Inc. (TSX: TOS) (“TSO3” or the “Company”), an innovator in sterilization technology for medical devices in healthcare settings, was named the winner of the South Carolina Chamber of Commerce’s SC Branded Product Innovation Award. This award follows the FDA clearance of the Company’s paradigm-shifting STERIZONE® VP4 Sterilizer to terminally sterilize multi-channeled flexible endoscopes in healthcare settings.

“We are honored to be the winner of the innovation award by the South Carolina Chamber of Commerce,” said R.M. (Ric) Rumble, TSO3’s President and CEO. “TSO3’s STERIZONE VP4 Sterilizer has the potential to impact millions of patients in the US and worldwide.  As a Canadian-based company that has established our US headquarters in Myrtle Beach, we have been made to feel welcome.  Our Myrtle Beach facility includes administrative offices, an educational lab for customers, as well as customer support and a compatibility testing facility.”

According to the U.S. Centers for Disease Control and Prevention (“CDC”), at least two million Americans are infected with antibiotic-resistant bacteria each year, and more than 23,000 of them die. Included in those statistics are patients who were infected in healthcare settings. One type of antibiotic-resistant infection that was traced to contaminated endoscopes was caused by Carbapenemresistant Enterobacteriaceae (CRE), a bacteria the CDC has designated as a “superbug”.

Click here for an interview with the widow of a patient in North Carolina who contracted CRE following an ERCP medical procedure.

“Recent and highly publicized infection outbreaks associated with use of flexible endoscopes in the United States and Canada have highlighted the need for innovative approaches to reprocessing these complex medical devices,” said Rumble. “Our advanced technology meets that need.”

The SC Branded Product Innovation Award recognizes the company whose newest development is bringing attention and growth to South Carolina. The STERIZONE VP4 Sterilizer is the only terminal sterilization method that is FDA cleared and validated to sterilize multi-channeled flexible endoscopes (with a maximum of four channels) of up to 3.5 meters in length, such as video colonoscopes, duodenoscopes and gastroscopes – an industry first for any medical device sterilization process.

The STERIZONE VP4 Sterilizer is also the only cleared low temperature sterilizer that can process a mixed load consisting of general instruments, single channel flexible endoscopes, and single or double channel rigid endoscopes in the same cycle, with load weights of up to 75 lb.

More information about the STERIZONE VP4 Sterilizer is available through TSO3‘s website, under the Products section at http://www.tso3.com/en/products/sterizone-vp4/.

The South Carolina Chamber is a statewide organization whose leading goal is to create an environment where businesses in all fields can combine their respective expertise with a vision of making South Carolina the ideal place for life, work and business. For more information on the SC Branded Program, see www.scbranded.com.

About TSO3

Founded in 1998, TSO3‘s activities encompass the sale, production, maintenance, research, development and licensing of sterilization processes, related consumable supplies and accessories for heat-sensitive medical devices. The Company designs products for sterile processing areas in the hospital environment that offer an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. TSO3 also offers services related to the maintenance of sterilization equipment and compatibility testing of medical devices with such processes.

For more information about TSO3, visit the Company’s website at www.tso3.com.

The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, the limited history of sales or distribution of the Company, the ability of the Company to obtain the required regulatory clearances to market its products, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties. Although TSO3 believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. The complete versions of the cautionary note regarding forward-looking statements as well as a description of the relevant assumptions and risk factors likely to affect TSO3’s actual or projected results are included in the Management’s Discussion and Analysis for the year ended December 31, 2017, which is available on the Company’s website. The forward-looking statements contained in this press release are made as of the date hereof, and TSO3 does not assume any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise unless expressly required by applicable securities laws.


Back to Posts